Current and emerging systemic treatment strategies for breast cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia, Pa. [u.a.]
Saunders
2007
|
| Schriftenreihe: | Hematology, oncology clinics of North America
21,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII S., S. 207 - 394 Ill., graph. Darst. |
| ISBN: | 9781416043232 1416043233 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV022500141 | ||
| 003 | DE-604 | ||
| 005 | 20080819 | ||
| 007 | t | ||
| 008 | 070709s2007 ad|| |||| 00||| eng d | ||
| 020 | |a 9781416043232 |9 978-1-4160-4323-2 | ||
| 020 | |a 1416043233 |9 1-4160-4323-3 | ||
| 035 | |a (OCoLC)146343899 | ||
| 035 | |a (DE-599)BVBBV022500141 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-29 |a DE-355 | ||
| 084 | |a XH 8455 |0 (DE-625)152958:13134 |2 rvk | ||
| 084 | |a YC 1700 |0 (DE-625)153192: |2 rvk | ||
| 245 | 1 | 0 | |a Current and emerging systemic treatment strategies for breast cancer |c guest ed.: Andrew D. Seidman |
| 264 | 1 | |a Philadelphia, Pa. [u.a.] |b Saunders |c 2007 | |
| 300 | |a XII S., S. 207 - 394 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Hematology, oncology clinics of North America |v 21,2 | |
| 650 | 4 | |a Breast Neoplasms |x therapy | |
| 650 | 4 | |a Breast |x Cancer |x Treatment | |
| 650 | 0 | 7 | |a Systemische Therapie |g Pharmakologie |0 (DE-588)4314641-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Brustkrebs |0 (DE-588)4008528-4 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Brustkrebs |0 (DE-588)4008528-4 |D s |
| 689 | 0 | 1 | |a Systemische Therapie |g Pharmakologie |0 (DE-588)4314641-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Seidman, Andrew |e Sonstige |4 oth | |
| 830 | 0 | |a Hematology, oncology clinics of North America |v 21,2 |w (DE-604)BV000625446 |9 21,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015707212&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015707212 | ||
Datensatz im Suchindex
| _version_ | 1804136598879600640 |
|---|---|
| adam_text | CONTENTS VOLUME 21 » NUMBER 2 ¦ APRIL 2007
Preface xi
Andrew D. Seidman
Adjuvant Chemotherapy for Early Stage Breast Cancer 207
Heather L. McArthur and Clifford A. Hudis
Systemic chemotherapy is an integral component of the adjuvant treat¬
ment strategy for women who have early stage breast cancer and
accounts for significant improvements in breast cancer specific mortal¬
ity. Decisions regarding adjuvant therapy are increasingly complex with
the advent of new therapeutic strategies, a growing body of literature on
the molecular biology and natural history of breast cancer, and ad¬
vances in therapeutic techniques and early detection. Ultimately, the
risk benefit calculus will continue to evolve in response to these ad¬
vances and one hopes that clinicians will soon be able to tailor treatment
recommendations to the biology of an individual cancer and the needs
of the affected individual.
Adjuvant Endocrine Treatment of Early Breast Cancer 223
Per Eystein Lenning
Endocrine therapy plays a pivotal role in the early treatment of estrogen
receptor (ER) positive breast cancer. Although evidence suggests that
chemotherapy may work partly through ovarian ablation in young
women who have ER positive tumors, combined chemotherapy and en¬
docrine therapy are generally advocated. In postmenopausal women, ar
omatase inhibition has become the new gold standard of treatment.
More research is needed to define optimal regimens (aromatase inhibitor
monotherapy versus tamoxifen sequential application), optimal duration
of therapy and potential advantages of particular compounds. The opti¬
mal use of estrogen suppression (ovarian ablation with or without aroma¬
tase inhibition) and tamoxifen (administered sequentially or in concert
with ovarian ablation) in premenopausal women has yet to be defined.
Trastuzumab (Herceptin) for Early Stage Breast Cancer 239
Gustavo Ismael, Daniela Dornelles Rosa,
Evandro de Azambuja, Sofia Braga, and Martine
Piccart Gebhart
Breast cancer patients who have HER2 gene amplification and, conse
quendy, protein overexpression, generally show an aggressive course
v
CONTENTS continued
with short disease free and overall survivals. Trastuzumab, a humanized
monoclonal antibody against the extracellular domain of HER2 protein,
has been shown to benefit patients who have HER2 positive metastatic
breast cancer, and recently, the results of five adjuvant trials involving
more than 13,000 women have been released. Here, the authors sum¬
marize the main results and outline the differences among these trials,
which have demonstrated an important role of trastuzumab in the treat¬
ment of women who have HER2 overexpressing/amplified early breast
cancer.
Chemotherapy for Metastatic Breast Cancer 257
Erica L. Mayer and Harold J. Burstein
Cytotoxic chemotherapy is a mainstay of treatment for advanced breast
cancer. Treatment of metastatic (also called stage IV, advanced, or recur¬
rent) breast cancer is not considered curative. Rather, the goals of treat¬
ment with chemotherapy are to prolong survival, alleviate or prevent
tumor related symptoms or complications, and improve quality of life.
While the purpose of chemotherapy is to prevent or alleviate symptoms,
chemotherapy paradoxically carries considerable toxicities that cause
substantial symptoms in patients, notoriously including fatigue, nausea,
vomiting, diarrhea, hair loss, mucositis, neutropenia, and neuropathy.
Balancing the benefits and the side effects of chemotherapy is further
complicated by the natural history of advanced breast cancer, which
can be quite prolonged and typically involves multiple lines of chemo¬
therapy, especially in patients whose tumors respond to treatment.
Hormonal Therapy for Advanced Breast Cancer 273
Hope S. Rugo
Hormonal therapy for advanced breast cancer has evolved significantly
in the more than 100 years since the first publications documenting the
effect of ovarian ablation on advanced breast cancer in premenopausal
women. Since that time, not only have we developed the methods to
measure estrogen and progesterone receptors in cancer cells, but
more recently we have understood that expression of these receptors
determines response to hormone therapy. The availability of more se¬
lective antiestrogen therapies has changed and significantly improved
the treatment options for women who have advanced hormone respon¬
sive breast cancer. Current research is focusing on reversing resistance
to hormone therapy with the addition of targeted biologic agents to
standard hormonal treatment.
HER2 Positive Advanced Breast Cancer 293
Nicholas J. Robert and Anne M. Favret
It is important when treating a patient who has advanced breast cancer
to establish the biologic characteristics of the tumor. In addition to
knowing the hormone receptor status (estrogen and progesterone),
human epidermal receptor 2 (HER2) should be evaluated. The
CONTENTS continued
measurement of this parameter is essential to optimizing the systemic
management. This article reviews the biology of HER2, testing for
HER2, clinical studies evaluating HER2 based therapies, side effects
(specifically cardiotoxicity), and strategies for HER2 based therapies.
Bevacizumab for Advanced Breast Cancer 303
Tiffany A. Traina, Hope S. Rugo, and Maura Didder
Tumor angiogenesis is essential for the growth and metastasis of solid
tumors. In breast cancer, increased levels of vascular endothelial growth
factor (VEGF) have been associated with poor prognosis in lymph node
positive and lymph node negative patients. In addition to its prognostic
significance, VEGF is now a validated target in the treatment of breast
cancer. Bevacizumab, an and VEGF antibody, has demonstrated signifi¬
cant clinical benefit in several solid tumors. In this article the authors dis¬
cuss the data pertaining to bevacizumab and other antiangiogenic agents
for the treatment of patients who have advanced breast cancer.
Emerging Targeted Therapies for Breast Cancer 321
Monica Arnedos and Andrew D. Seidman
Breast cancer is the most common neoplasia among women in the world.
For the last few years there has been an increasing interest in the devel¬
opment of agents against molecular targets considered to be involved
in the process of malignant transformation or tumor progression. Exper¬
imental data indicate that various intracellular signaling pathways may be
activated or overexpressed in patients who have breast cancer. Targeted
therapies against these pathways have recently become one of the most
active and promising areas of development in oncology.
Bisphosphonates for Breast Cancer: Questions
Answered, Questions Remaining 341
Rachel Layman, Karin Olson, and Catherine Van Poznak
Bone is an important organ that is essential to adult hematopoiesis, elec¬
trolyte balance, and locomotion. Individuals who have metastatic breast
cancer involving the bone are at increased risk for skeletal complica¬
tions and those who have a history of early stage breast cancer may
be at increased risk for fragility fractures. Maintaining bone integrity
is critical to control the morbidity and mortality associated with frac¬
tures and other skeletal complications. The bisphosphonates have
been shown to be efficacious in decreasing the risk for skeletal compli¬
cations in cancer and in osteoporosis. The article reviews the use of bi¬
sphosphonates in patients who have breast cancer.
Brain Metastases: Old Problem, New Strategies 369
Teri D. Nguyen and Lauren E. Abrey
Brain metastases from breast cancer are a common complication of the
disease and alter the management of patients more than any other site
vii
CONTENTS continued
of distant progression. Certain subgroups of patients are at high risk for
developing CNS disease, warranting targeted research and perhaps
screening for occult disease. Data from studies that include other solid
tumor histologies provide the bulk of supporting evidence for the use of
therapies, such as steroids, antiepileptic drugs, surgery, and radiation.
However, there are several issues specific to brain metastases from
breast cancer illustrating that this disease should be considered patho
physiologically distinct, and future research should be tailored
accordingly.
Index 389
|
| adam_txt |
CONTENTS VOLUME 21 » NUMBER 2 ¦ APRIL 2007
Preface xi
Andrew D. Seidman
Adjuvant Chemotherapy for Early Stage Breast Cancer 207
Heather L. McArthur and Clifford A. Hudis
Systemic chemotherapy is an integral component of the adjuvant treat¬
ment strategy for women who have early stage breast cancer and
accounts for significant improvements in breast cancer specific mortal¬
ity. Decisions regarding adjuvant therapy are increasingly complex with
the advent of new therapeutic strategies, a growing body of literature on
the molecular biology and natural history of breast cancer, and ad¬
vances in therapeutic techniques and early detection. Ultimately, the
risk benefit calculus will continue to evolve in response to these ad¬
vances and one hopes that clinicians will soon be able to tailor treatment
recommendations to the biology of an individual cancer and the needs
of the affected individual.
Adjuvant Endocrine Treatment of Early Breast Cancer 223
Per Eystein Lenning
Endocrine therapy plays a pivotal role in the early treatment of estrogen
receptor (ER) positive breast cancer. Although evidence suggests that
chemotherapy may work partly through ovarian ablation in young
women who have ER positive tumors, combined chemotherapy and en¬
docrine therapy are generally advocated. In postmenopausal women, ar
omatase inhibition has become the new "gold standard" of treatment.
More research is needed to define optimal regimens (aromatase inhibitor
monotherapy versus tamoxifen sequential application), optimal duration
of therapy and potential advantages of particular compounds. The opti¬
mal use of estrogen suppression (ovarian ablation with or without aroma¬
tase inhibition) and tamoxifen (administered sequentially or in concert
with ovarian ablation) in premenopausal women has yet to be defined.
Trastuzumab (Herceptin) for Early Stage Breast Cancer 239
Gustavo Ismael, Daniela Dornelles Rosa,
Evandro de Azambuja, Sofia Braga, and Martine
Piccart Gebhart
Breast cancer patients who have HER2 gene amplification and, conse
quendy, protein overexpression, generally show an aggressive course
v
CONTENTS continued
with short disease free and overall survivals. Trastuzumab, a humanized
monoclonal antibody against the extracellular domain of HER2 protein,
has been shown to benefit patients who have HER2 positive metastatic
breast cancer, and recently, the results of five adjuvant trials involving
more than 13,000 women have been released. Here, the authors sum¬
marize the main results and outline the differences among these trials,
which have demonstrated an important role of trastuzumab in the treat¬
ment of women who have HER2 overexpressing/amplified early breast
cancer.
Chemotherapy for Metastatic Breast Cancer 257
Erica L. Mayer and Harold J. Burstein
Cytotoxic chemotherapy is a mainstay of treatment for advanced breast
cancer. Treatment of metastatic (also called stage IV, advanced, or recur¬
rent) breast cancer is not considered curative. Rather, the goals of treat¬
ment with chemotherapy are to prolong survival, alleviate or prevent
tumor related symptoms or complications, and improve quality of life.
While the purpose of chemotherapy is to prevent or alleviate symptoms,
chemotherapy paradoxically carries considerable toxicities that cause
substantial symptoms in patients, notoriously including fatigue, nausea,
vomiting, diarrhea, hair loss, mucositis, neutropenia, and neuropathy.
Balancing the benefits and the side effects of chemotherapy is further
complicated by the natural history of advanced breast cancer, which
can be quite prolonged and typically involves multiple lines of chemo¬
therapy, especially in patients whose tumors respond to treatment.
Hormonal Therapy for Advanced Breast Cancer 273
Hope S. Rugo
Hormonal therapy for advanced breast cancer has evolved significantly
in the more than 100 years since the first publications documenting the
effect of ovarian ablation on advanced breast cancer in premenopausal
women. Since that time, not only have we developed the methods to
measure estrogen and progesterone receptors in cancer cells, but
more recently we have understood that expression of these receptors
determines response to hormone therapy. The availability of more se¬
lective antiestrogen therapies has changed and significantly improved
the treatment options for women who have advanced hormone respon¬
sive breast cancer. Current research is focusing on reversing resistance
to hormone therapy with the addition of targeted biologic agents to
standard hormonal treatment.
HER2 Positive Advanced Breast Cancer 293
Nicholas J. Robert and Anne M. Favret
It is important when treating a patient who has advanced breast cancer
to establish the biologic characteristics of the tumor. In addition to
knowing the hormone receptor status (estrogen and progesterone),
human epidermal receptor 2 (HER2) should be evaluated. The
CONTENTS continued
measurement of this parameter is essential to optimizing the systemic
management. This article reviews the biology of HER2, testing for
HER2, clinical studies evaluating HER2 based therapies, side effects
(specifically cardiotoxicity), and strategies for HER2 based therapies.
Bevacizumab for Advanced Breast Cancer 303
Tiffany A. Traina, Hope S. Rugo, and Maura Didder
Tumor angiogenesis is essential for the growth and metastasis of solid
tumors. In breast cancer, increased levels of vascular endothelial growth
factor (VEGF) have been associated with poor prognosis in lymph node
positive and lymph node negative patients. In addition to its prognostic
significance, VEGF is now a validated target in the treatment of breast
cancer. Bevacizumab, an and VEGF antibody, has demonstrated signifi¬
cant clinical benefit in several solid tumors. In this article the authors dis¬
cuss the data pertaining to bevacizumab and other antiangiogenic agents
for the treatment of patients who have advanced breast cancer.
Emerging Targeted Therapies for Breast Cancer 321
Monica Arnedos and Andrew D. Seidman
Breast cancer is the most common neoplasia among women in the world.
For the last few years there has been an increasing interest in the devel¬
opment of agents against molecular targets considered to be involved
in the process of malignant transformation or tumor progression. Exper¬
imental data indicate that various intracellular signaling pathways may be
activated or overexpressed in patients who have breast cancer. Targeted
therapies against these pathways have recently become one of the most
active and promising areas of development in oncology.
Bisphosphonates for Breast Cancer: Questions
Answered, Questions Remaining 341
Rachel Layman, Karin Olson, and Catherine Van Poznak
Bone is an important organ that is essential to adult hematopoiesis, elec¬
trolyte balance, and locomotion. Individuals who have metastatic breast
cancer involving the bone are at increased risk for skeletal complica¬
tions and those who have a history of early stage breast cancer may
be at increased risk for fragility fractures. Maintaining bone integrity
is critical to control the morbidity and mortality associated with frac¬
tures and other skeletal complications. The bisphosphonates have
been shown to be efficacious in decreasing the risk for skeletal compli¬
cations in cancer and in osteoporosis. The article reviews the use of bi¬
sphosphonates in patients who have breast cancer.
Brain Metastases: Old Problem, New Strategies 369
Teri D. Nguyen and Lauren E. Abrey
Brain metastases from breast cancer are a common complication of the
disease and alter the management of patients more than any other site
vii
CONTENTS continued
of distant progression. Certain subgroups of patients are at high risk for
developing CNS disease, warranting targeted research and perhaps
screening for occult disease. Data from studies that include other solid
tumor histologies provide the bulk of supporting evidence for the use of
therapies, such as steroids, antiepileptic drugs, surgery, and radiation.
However, there are several issues specific to brain metastases from
breast cancer illustrating that this disease should be considered patho
physiologically distinct, and future research should be tailored
accordingly.
Index 389 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV022500141 |
| classification_rvk | XH 8455 YC 1700 |
| ctrlnum | (OCoLC)146343899 (DE-599)BVBBV022500141 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01723nam a2200409 cb4500</leader><controlfield tag="001">BV022500141</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080819 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070709s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416043232</subfield><subfield code="9">978-1-4160-4323-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416043233</subfield><subfield code="9">1-4160-4323-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)146343899</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022500141</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 8455</subfield><subfield code="0">(DE-625)152958:13134</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 1700</subfield><subfield code="0">(DE-625)153192:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current and emerging systemic treatment strategies for breast cancer</subfield><subfield code="c">guest ed.: Andrew D. Seidman</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia, Pa. [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII S., S. 207 - 394</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">21,2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Neoplasms</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Systemische Therapie</subfield><subfield code="g">Pharmakologie</subfield><subfield code="0">(DE-588)4314641-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Brustkrebs</subfield><subfield code="0">(DE-588)4008528-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Brustkrebs</subfield><subfield code="0">(DE-588)4008528-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Systemische Therapie</subfield><subfield code="g">Pharmakologie</subfield><subfield code="0">(DE-588)4314641-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seidman, Andrew</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">21,2</subfield><subfield code="w">(DE-604)BV000625446</subfield><subfield code="9">21,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015707212&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015707212</subfield></datafield></record></collection> |
| id | DE-604.BV022500141 |
| illustrated | Illustrated |
| index_date | 2024-07-02T17:55:08Z |
| indexdate | 2024-07-09T20:58:57Z |
| institution | BVB |
| isbn | 9781416043232 1416043233 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015707212 |
| oclc_num | 146343899 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-29 DE-355 DE-BY-UBR |
| owner_facet | DE-19 DE-BY-UBM DE-29 DE-355 DE-BY-UBR |
| physical | XII S., S. 207 - 394 Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Saunders |
| record_format | marc |
| series | Hematology, oncology clinics of North America |
| series2 | Hematology, oncology clinics of North America |
| spelling | Current and emerging systemic treatment strategies for breast cancer guest ed.: Andrew D. Seidman Philadelphia, Pa. [u.a.] Saunders 2007 XII S., S. 207 - 394 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Hematology, oncology clinics of North America 21,2 Breast Neoplasms therapy Breast Cancer Treatment Systemische Therapie Pharmakologie (DE-588)4314641-7 gnd rswk-swf Brustkrebs (DE-588)4008528-4 gnd rswk-swf Brustkrebs (DE-588)4008528-4 s Systemische Therapie Pharmakologie (DE-588)4314641-7 s DE-604 Seidman, Andrew Sonstige oth Hematology, oncology clinics of North America 21,2 (DE-604)BV000625446 21,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015707212&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Current and emerging systemic treatment strategies for breast cancer Hematology, oncology clinics of North America Breast Neoplasms therapy Breast Cancer Treatment Systemische Therapie Pharmakologie (DE-588)4314641-7 gnd Brustkrebs (DE-588)4008528-4 gnd |
| subject_GND | (DE-588)4314641-7 (DE-588)4008528-4 |
| title | Current and emerging systemic treatment strategies for breast cancer |
| title_auth | Current and emerging systemic treatment strategies for breast cancer |
| title_exact_search | Current and emerging systemic treatment strategies for breast cancer |
| title_exact_search_txtP | Current and emerging systemic treatment strategies for breast cancer |
| title_full | Current and emerging systemic treatment strategies for breast cancer guest ed.: Andrew D. Seidman |
| title_fullStr | Current and emerging systemic treatment strategies for breast cancer guest ed.: Andrew D. Seidman |
| title_full_unstemmed | Current and emerging systemic treatment strategies for breast cancer guest ed.: Andrew D. Seidman |
| title_short | Current and emerging systemic treatment strategies for breast cancer |
| title_sort | current and emerging systemic treatment strategies for breast cancer |
| topic | Breast Neoplasms therapy Breast Cancer Treatment Systemische Therapie Pharmakologie (DE-588)4314641-7 gnd Brustkrebs (DE-588)4008528-4 gnd |
| topic_facet | Breast Neoplasms therapy Breast Cancer Treatment Systemische Therapie Pharmakologie Brustkrebs |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015707212&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625446 |
| work_keys_str_mv | AT seidmanandrew currentandemergingsystemictreatmentstrategiesforbreastcancer |